[{"id":"3fec226c-b683-4fc3-8582-fb3594fac2b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922752","created_at":"2021-01-18T08:40:44.841Z","updated_at":"2024-07-02T16:36:20.800Z","phase":"Phase 1","brief_title":"To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01922752","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEP-37440"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2021-11-12"}]